Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jane Wu

Pulmonary Disease Fairfax, VA Medical Doctor

NPI 1063414399 CMS profile 2270

3650 Joseph Siewick Dr, Ste 307, Fairfax, VA 22033

Open in the dashboard

General payments

$7,418

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jane Wu of Fairfax, VA is reported in the CMS Open Payments database as having received $7,418 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,105 47
2024 General $1,491 55
2023 General $1,556 60
2022 General $1,315 47
2021 General $634 31
2020 General $156 8
2019 General $1,160 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Wu
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jane Wu were reported at $1,105. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jane Wu Pulmonary Disease median Middle half National median
2019 $1,160 $377 $109–$1,340 $163
2020 $156 $230 $56–$907 $114
2021 $634 $269 $68–$1,072 $132
2022 $1,315 $390 $100–$1,457 $149
2023 $1,556 $419 $114–$1,659 $160
2024 $1,491 $476 $123–$1,818 $164
2025 $1,105 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,273 94 payments
  2. Regeneron Healthcare Solutions, Inc. $1,038 48 payments
  3. GlaxoSmithKline, LLC. $772 31 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $430 13 payments
  5. Mylan Specialty L.P. $320 12 payments
  6. Grifols USA, LLC $263 10 payments
  7. Inspire Medical Systems, Inc. $260 6 payments
  8. Genentech USA, Inc. $251 2 payments
  9. Genzyme Corporation $248 9 payments
  10. Insmed, Inc. $199 8 payments
  11. Other $1,365 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,312 287 payments
  2. Education $92 2 payments
  3. Entertainment $14 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $965 45 payments
  2. BREZTRI $877 34 payments
  3. TRELEGY ELLIPTA $440 21 payments
  4. FASENRA $378 16 payments
  5. TEZSPIRE $368 16 payments
  6. AIRSUPRA $359 13 payments
  7. NUCALA $313 9 payments
  8. YUPELRI $307 12 payments
  9. DUPIXENT Immunology $307 9 payments
  10. Prolastin-C Liquid $263 10 payments
  11. Other $3,141 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,633

Median for Pulmonary Disease: 936

Drug cost

$447,414

Median for Pulmonary Disease: $487,987

Branded share of claims

25%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 169 $250,967
Tezspire Tezepelumab-Ekko Brand 15 $66,874
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 31 $34,787
Breo Ellipta Fluticasone/Vilanterol Brand 36 $29,733
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 40 $9,139
Symbicort Budesonide/Formoterol Fumarate Brand 15 $8,089
Azelastine Hcl Generic 142 $7,366
Jardiance Empagliflozin Brand 12 $7,205
Montelukast Sodium Generic 440 $6,547
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $5,027

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$164,753

Medicare's payments for the services billed

Medicare patients

318

Average age 76

Services billed

2,802

186 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
COPD 38%
Ischemic heart disease 34%
Diabetes 29%
Heart failure 25%
Atrial fibrillation 25%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $270
  • SANOFI-AVENTIS U.S. LLC $80
  • GENZYME CORPORATION $61
$411 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $340
$340 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $115
  • Amgen Inc. $25
$140 15 —
YUPELRI
  • Mylan Specialty L.P. $85
$85 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record